SCHEMBL9890729

SCHEMBL9890729

CCNC(=O)Cc1cc(Cl)ccc1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.47
SHMT1 P34896 5/20 0.46
SHMT2 P34897 3/20 0.46
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
THRB P10828 1/20 0.44
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
P2RX7 Q99572 3/20 0.42
ADAMTS4 O75173 1/20 0.42
ADAMTS5 Q9UNA0 1/20 0.42
PLA2G1B P04054 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890728 0.86 FFAR1 (0.46) HPGDSHMT1SHMT2FFAR1FFAR4
SCHEMBL3738386 0.81 FFAR1 (0.54) SHMT1SHMT2FFAR1FFAR4KDM4E
SCHEMBL17545797 0.78 FFAR1 (0.48) HPGDFFAR1FFAR4ALDH1A1TSHR
SCHEMBL9393209 0.78 KDM4E (0.49) HPGDALDH1A1LMNATSHRSMN1; SMN2
SCHEMBL9890727 0.78 FFAR1 (0.49) HPGDSHMT1SHMT2FFAR1FFAR4
SCHEMBL8424664 0.76 ERCC1 (0.61) HPGDLMNATSHRNPC1RAB9A
Glyoxylate SCHEMBL7971642 0.75 FFAR1 (0.47) SHMT1SHMT2FFAR1FFAR4KMT2A
SCHEMBL17151444 0.75 DDR1 (0.48) HPGDTSHR
SCHEMBL2393525 0.74 PTGDR2 (0.47) HPGDSHMT1SHMT2FFAR1FFAR4
SCHEMBL25252399 0.74 TSHR (0.47) HPGDLMNATSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HPGD 3524/4885SHMT1 1479/4885SHMT2 1195/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 HPGD 3524/4885SHMT1 1479/4885SHMT2 1195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.